Aripiprazole (Abilify) vs Aripiprazole (Abilify Maintena)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Schizophrenia

Shared mechanism: Dopamine D2/D3 and serotonin 5-HT1A receptor · full Schizophrenia pipeline

Aripiprazole (Abilify)

Marketed by Otsuka Holdings and partners

Approved in Schizophreniasmall molecule
Partial signal

NCT00712686 · Phase 3 · completed

A randomised, double-blind, active-controlled trial of aripiprazole (n=355) against olanzapine (n=348) in acute schizophrenia, with two co-primary objectives. The published results are mixed: olanzapine was statistically superior on PANSS efficacy at week 6, so aripiprazole did not show non-inferiority, while aripiprazole caused significantly less weight gain at week 26. The registry has no posted results; the figures are from the publication (Fleischhacker et al., Biol Psychiatry 2009).

Next expected readout: July 2030 · NCT06969755 (registry estimate)

Reported efficacy

The mean change in the PANSS Total Score (from baseline to Week 6); The percentage of patients showing significant weight gain (a≥ 7% increase) (from baseline to Week 26): Mean change in PANSS Total Score from baseline to Week 6: aripiprazole -24.6 vs olanzapine -29.5 (random regression model); treatment difference 4.9 points, 95% CI 2.2-7.6, exceeding the pre-specified 6-point non-inferiority margin -- aripiprazole did not reach non-inferiority (olanzapine was statistically superior). Aripiprazole showed significantly less weight gain at Week 26: +0.13 kg vs +4.30 kg for olanzapine, and fewer patients with significant weight gain (21% vs 40%, p<.05). (mixed)

Result source: NCT00712686

Aripiprazole (Abilify Maintena)

Marketed by Otsuka Holdings and partners

Approved in Schizophreniasmall molecule
Reliable signal

NCT00706654 · Phase 3 · completed

This was a randomized, double-blind, active-controlled trial with 662 randomized maintenance-phase participants, including 265 assigned to depot 300/400 mg and 266 to oral aripiprazole. The primary clinical relapse endpoint was met: depot treatment was non-inferior to oral aripiprazole, with a difference of -0.64 percentage points and a 95% confidence interval of -5.26 to 3.99, below the prespecified 11.5% margin.

Reported efficacy

Mean change from baseline to endpoint(10th week)in PANSS Total Score. (1st,2nd,4th,6th,8th,10th,12th week): LS mean change from baseline to Week 10 in PANSS Total Score: -33.6 (aripiprazole once-monthly, AOM) vs -34.8 (oral aripiprazole); difference -1.2 (95% CI: -4.1, 1.7), within the pre-defined non-inferiority margin (met)

Result source: NCT03172871

Results for Schizophrenia

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointAripiprazole (Abilify)Aripiprazole (Abilify Maintena)
PANSS total, change-26.7 vs -21.2−5.5 vs placebo10 mg/day · wk 6 · n 99NCT00102063
31 other results
  • -28.6 vs -21.2 30 mg/day · wk 6 · n 97 · Phase 3 · primary NCT00102063
  • -19.4 vs -22.9 wk 6 · n 33 · Phase 3 · primary NCT02054702
  • -1.2 vs 3.9 wk 10 · n 98 · Phase 3 · secondary NCT01149655
  • -1.6 vs 3.7 wk 8 · n 98 · Phase 3 · secondary NCT01149655
  • -0.2 vs 4.5 wk 12 · n 98 · Phase 3 · secondary NCT01149655
  • -1.2 vs 2.9 wk 6 · n 98 · Phase 3 · secondary NCT01149655
  • -0.2 vs 5.5 wk 14 · n 98 · Phase 3 · secondary NCT01149655
  • -0.6 vs 1.6 wk 4 · n 98 · Phase 3 · secondary NCT01149655
  • -0.8 vs 5.6 wk 16 · n 98 · Phase 3 · secondary NCT01149655
  • -0.4 vs 1.8 wk 3 · n 98 · Phase 3 · secondary NCT01149655
  • 0.1 vs -0.6 wk 2 · n 98 · Phase 3 · secondary NCT01149655
  • -0.7 vs 5.6 wk 18 · n 98 · Phase 3 · secondary NCT01149655
  • 0.2 vs -0.3 wk 1 · n 98 · Phase 3 · secondary NCT01149655
  • -0.6 vs 6.1 wk 20 · n 98 · Phase 3 · secondary NCT01149655
  • -0.3 vs 6.1 wk 22 · n 98 · Phase 3 · secondary NCT01149655
  • -0.4 vs 5.9 wk 24 · n 98 · Phase 3 · secondary NCT01149655
  • -0.9 vs 5.8 wk 26 · n 98 · Phase 3 · secondary NCT01149655
  • -0.8 vs 5.7 wk 28 · n 98 · Phase 3 · secondary NCT01149655
  • -1.0 vs 5.6 wk 30 · n 98 · Phase 3 · secondary NCT01149655
  • -1.0 vs 6.2 wk 32 · n 98 · Phase 3 · secondary NCT01149655
  • -1.1 vs 5.8 wk 34 · n 98 · Phase 3 · secondary NCT01149655
  • -0.6 vs 5.4 wk 36 · n 98 · Phase 3 · secondary NCT01149655
  • -0.8 vs 5.2 wk 38 · n 98 · Phase 3 · secondary NCT01149655
  • -0.9 vs 5.1 wk 40 · n 98 · Phase 3 · secondary NCT01149655
  • -1.1 vs 4.9 wk 42 · n 98 · Phase 3 · secondary NCT01149655
  • -1.0 vs 4.9 wk 44 · n 98 · Phase 3 · secondary NCT01149655
  • -1.0 vs 4.8 wk 46 · n 98 · Phase 3 · secondary NCT01149655
  • -1.0 vs 4.7 wk 48 · n 98 · Phase 3 · secondary NCT01149655
  • -1.2 vs 4.7 wk 50 · n 98 · Phase 3 · secondary NCT01149655
  • -1.3 vs 4.8 wk 52 · n 98 · Phase 3 · secondary NCT01149655
  • -7.7 vs -9.3 wk 104 · n 44 · Phase 3 · secondary NCT00216476
-26.8 vs -11.7−15.1 vs placebo400/300 mg · wk 10 · n 162NCT01663532
6 other results
  • -23.7 vs -9.7 400/300 mg · wk 8 · n 162 · Phase 3 · primary NCT01663532
  • -21.5 vs -10.3 400/300 mg · wk 6 · n 162 · Phase 3 · primary NCT01663532
  • -19 vs -9.8 400/300 mg · wk 4 · n 162 · Phase 3 · primary NCT01663532
  • -15.2 vs -8.3 400/300 mg · wk 2 · n 162 · Phase 3 · primary NCT01663532
  • -8.9 vs -5 400/300 mg · wk 1 · n 162 · Phase 3 · primary NCT01663532
  • -33.6 vs -34.8 wk 10 · Phase 3 · primary NCT03172871
CGI-S, change-1.2 vs -0.9−0.3 vs placebo10 mg/day · wk 6 · n 99NCT00102063
32 other results
  • -1.3 vs -0.9 30 mg/day · wk 6 · n 97 · Phase 3 · secondary NCT00102063
  • 0.1 vs 0.3 wk 28 · n 98 · Phase 3 · secondary NCT01149655
  • 0.1 vs 0.3 wk 26 · n 98 · Phase 3 · secondary NCT01149655
  • 0.0 vs 0.3 wk 30 · n 98 · Phase 3 · secondary NCT01149655
  • 0.1 vs 0.3 wk 24 · n 98 · Phase 3 · secondary NCT01149655
  • 0.0 vs 0.3 wk 32 · n 98 · Phase 3 · secondary NCT01149655
  • 0.1 vs 0.4 wk 22 · n 98 · Phase 3 · secondary NCT01149655
  • 0.1 vs 0.3 wk 34 · n 98 · Phase 3 · secondary NCT01149655
  • 0.1 vs 0.4 wk 20 · n 98 · Phase 3 · secondary NCT01149655
  • 0.1 vs 0.3 wk 36 · n 98 · Phase 3 · secondary NCT01149655
  • 0.0 vs 0.3 wk 18 · n 98 · Phase 3 · secondary NCT01149655
  • 0.1 vs 0.3 wk 38 · n 98 · Phase 3 · secondary NCT01149655
  • 0.0 vs 0.3 wk 16 · n 98 · Phase 3 · secondary NCT01149655
  • 0.1 vs 0.3 wk 40 · n 98 · Phase 3 · secondary NCT01149655
  • 0.0 vs 0.3 wk 14 · n 98 · Phase 3 · secondary NCT01149655
  • 0.1 vs 0.3 wk 42 · n 98 · Phase 3 · secondary NCT01149655
  • 0.1 vs 0.3 wk 12 · n 98 · Phase 3 · secondary NCT01149655
  • 0.1 vs 0.3 wk 44 · n 98 · Phase 3 · secondary NCT01149655
  • 0.0 vs 0.3 wk 10 · n 98 · Phase 3 · secondary NCT01149655
  • 0.1 vs 0.3 wk 46 · n 98 · Phase 3 · secondary NCT01149655
  • 0.0 vs 0.2 wk 8 · n 98 · Phase 3 · secondary NCT01149655
  • 0.1 vs 0.3 wk 48 · n 98 · Phase 3 · secondary NCT01149655
  • 0.0 vs 0.1 wk 6 · n 98 · Phase 3 · secondary NCT01149655
  • 0.1 vs 0.3 wk 50 · n 98 · Phase 3 · secondary NCT01149655
  • 0.0 vs 0.1 wk 4 · n 98 · Phase 3 · secondary NCT01149655
  • 0.1 vs 0.3 wk 52 · n 98 · Phase 3 · secondary NCT01149655
  • 0.0 vs 0.1 wk 3 · n 98 · Phase 3 · secondary NCT01149655
  • 0 vs 0.0 wk 2 · n 98 · Phase 3 · secondary NCT01149655
  • 0.0 vs 0.0 wk 1 · n 98 · Phase 3 · secondary NCT01149655
  • -0.8 vs -0.5 wk 28 · n 136 · Phase 3 · secondary NCT01795547
  • -1.3 vs -1.6 wk 6 · n 33 · Phase 3 · secondary NCT02054702
  • -0.1 vs -0.3 wk 104 · n 44 · Phase 3 · secondary NCT00216476
-1.4 vs -0.6−0.8 vs placebo400/300 mg · wk 10 · n 162NCT01663532
6 other results
  • -1.3 vs -0.6 400/300 mg · wk 8 · n 162 · Phase 3 · secondary NCT01663532
  • -1.2 vs -0.5 400/300 mg · wk 6 · n 162 · Phase 3 · secondary NCT01663532
  • -1 vs -0.4 400/300 mg · wk 4 · n 162 · Phase 3 · secondary NCT01663532
  • -0.8 vs -0.4 400/300 mg · wk 2 · n 162 · Phase 3 · secondary NCT01663532
  • -0.4 vs -0.2 400/300 mg · wk 1 · n 162 · Phase 3 · secondary NCT01663532
  • -0.8 vs -0.5 wk 28 · n 136 · Phase 3 · secondary NCT01795547
PANSS response—Not posted · NCT0348541737% vs 14.3%+22.7 vs placebo400/300 mg · wk 10 · n 162NCT01663532
PSP, change—Not posted · NCT0348541712.3 vs 5.2+7.1 vs placebo400/300 mg · wk 10 · n 139NCT01663532
Relapse (% of patients)19.4% vs 37.5%−18.1 vs placebowk 52 · n 98NCT01149655
1 other result
  • 10% vs 39.6% wk 52 · n 269 · Phase 3 · secondary NCT00705783
10% vs 39.6%−29.6 vs placebowk 52 · n 269NCT00705783

PANSS total, change

Aripiprazole (Abilify)
-26.7 vs -21.2−5.5 vs placebo10 mg/day · wk 6 · n 99NCT00102063
31 other results
  • -28.6 vs -21.2 30 mg/day · wk 6 · n 97 · Phase 3 · primary NCT00102063
  • -19.4 vs -22.9 wk 6 · n 33 · Phase 3 · primary NCT02054702
  • -1.2 vs 3.9 wk 10 · n 98 · Phase 3 · secondary NCT01149655
  • -1.6 vs 3.7 wk 8 · n 98 · Phase 3 · secondary NCT01149655
  • -0.2 vs 4.5 wk 12 · n 98 · Phase 3 · secondary NCT01149655
  • -1.2 vs 2.9 wk 6 · n 98 · Phase 3 · secondary NCT01149655
  • -0.2 vs 5.5 wk 14 · n 98 · Phase 3 · secondary NCT01149655
  • -0.6 vs 1.6 wk 4 · n 98 · Phase 3 · secondary NCT01149655
  • -0.8 vs 5.6 wk 16 · n 98 · Phase 3 · secondary NCT01149655
  • -0.4 vs 1.8 wk 3 · n 98 · Phase 3 · secondary NCT01149655
  • 0.1 vs -0.6 wk 2 · n 98 · Phase 3 · secondary NCT01149655
  • -0.7 vs 5.6 wk 18 · n 98 · Phase 3 · secondary NCT01149655
  • 0.2 vs -0.3 wk 1 · n 98 · Phase 3 · secondary NCT01149655
  • -0.6 vs 6.1 wk 20 · n 98 · Phase 3 · secondary NCT01149655
  • -0.3 vs 6.1 wk 22 · n 98 · Phase 3 · secondary NCT01149655
  • -0.4 vs 5.9 wk 24 · n 98 · Phase 3 · secondary NCT01149655
  • -0.9 vs 5.8 wk 26 · n 98 · Phase 3 · secondary NCT01149655
  • -0.8 vs 5.7 wk 28 · n 98 · Phase 3 · secondary NCT01149655
  • -1.0 vs 5.6 wk 30 · n 98 · Phase 3 · secondary NCT01149655
  • -1.0 vs 6.2 wk 32 · n 98 · Phase 3 · secondary NCT01149655
  • -1.1 vs 5.8 wk 34 · n 98 · Phase 3 · secondary NCT01149655
  • -0.6 vs 5.4 wk 36 · n 98 · Phase 3 · secondary NCT01149655
  • -0.8 vs 5.2 wk 38 · n 98 · Phase 3 · secondary NCT01149655
  • -0.9 vs 5.1 wk 40 · n 98 · Phase 3 · secondary NCT01149655
  • -1.1 vs 4.9 wk 42 · n 98 · Phase 3 · secondary NCT01149655
  • -1.0 vs 4.9 wk 44 · n 98 · Phase 3 · secondary NCT01149655
  • -1.0 vs 4.8 wk 46 · n 98 · Phase 3 · secondary NCT01149655
  • -1.0 vs 4.7 wk 48 · n 98 · Phase 3 · secondary NCT01149655
  • -1.2 vs 4.7 wk 50 · n 98 · Phase 3 · secondary NCT01149655
  • -1.3 vs 4.8 wk 52 · n 98 · Phase 3 · secondary NCT01149655
  • -7.7 vs -9.3 wk 104 · n 44 · Phase 3 · secondary NCT00216476
Aripiprazole (Abilify Maintena)
-26.8 vs -11.7−15.1 vs placebo400/300 mg · wk 10 · n 162NCT01663532
6 other results
  • -23.7 vs -9.7 400/300 mg · wk 8 · n 162 · Phase 3 · primary NCT01663532
  • -21.5 vs -10.3 400/300 mg · wk 6 · n 162 · Phase 3 · primary NCT01663532
  • -19 vs -9.8 400/300 mg · wk 4 · n 162 · Phase 3 · primary NCT01663532
  • -15.2 vs -8.3 400/300 mg · wk 2 · n 162 · Phase 3 · primary NCT01663532
  • -8.9 vs -5 400/300 mg · wk 1 · n 162 · Phase 3 · primary NCT01663532
  • -33.6 vs -34.8 wk 10 · Phase 3 · primary NCT03172871

CGI-S, change

Aripiprazole (Abilify)
-1.2 vs -0.9−0.3 vs placebo10 mg/day · wk 6 · n 99NCT00102063
32 other results
  • -1.3 vs -0.9 30 mg/day · wk 6 · n 97 · Phase 3 · secondary NCT00102063
  • 0.1 vs 0.3 wk 28 · n 98 · Phase 3 · secondary NCT01149655
  • 0.1 vs 0.3 wk 26 · n 98 · Phase 3 · secondary NCT01149655
  • 0.0 vs 0.3 wk 30 · n 98 · Phase 3 · secondary NCT01149655
  • 0.1 vs 0.3 wk 24 · n 98 · Phase 3 · secondary NCT01149655
  • 0.0 vs 0.3 wk 32 · n 98 · Phase 3 · secondary NCT01149655
  • 0.1 vs 0.4 wk 22 · n 98 · Phase 3 · secondary NCT01149655
  • 0.1 vs 0.3 wk 34 · n 98 · Phase 3 · secondary NCT01149655
  • 0.1 vs 0.4 wk 20 · n 98 · Phase 3 · secondary NCT01149655
  • 0.1 vs 0.3 wk 36 · n 98 · Phase 3 · secondary NCT01149655
  • 0.0 vs 0.3 wk 18 · n 98 · Phase 3 · secondary NCT01149655
  • 0.1 vs 0.3 wk 38 · n 98 · Phase 3 · secondary NCT01149655
  • 0.0 vs 0.3 wk 16 · n 98 · Phase 3 · secondary NCT01149655
  • 0.1 vs 0.3 wk 40 · n 98 · Phase 3 · secondary NCT01149655
  • 0.0 vs 0.3 wk 14 · n 98 · Phase 3 · secondary NCT01149655
  • 0.1 vs 0.3 wk 42 · n 98 · Phase 3 · secondary NCT01149655
  • 0.1 vs 0.3 wk 12 · n 98 · Phase 3 · secondary NCT01149655
  • 0.1 vs 0.3 wk 44 · n 98 · Phase 3 · secondary NCT01149655
  • 0.0 vs 0.3 wk 10 · n 98 · Phase 3 · secondary NCT01149655
  • 0.1 vs 0.3 wk 46 · n 98 · Phase 3 · secondary NCT01149655
  • 0.0 vs 0.2 wk 8 · n 98 · Phase 3 · secondary NCT01149655
  • 0.1 vs 0.3 wk 48 · n 98 · Phase 3 · secondary NCT01149655
  • 0.0 vs 0.1 wk 6 · n 98 · Phase 3 · secondary NCT01149655
  • 0.1 vs 0.3 wk 50 · n 98 · Phase 3 · secondary NCT01149655
  • 0.0 vs 0.1 wk 4 · n 98 · Phase 3 · secondary NCT01149655
  • 0.1 vs 0.3 wk 52 · n 98 · Phase 3 · secondary NCT01149655
  • 0.0 vs 0.1 wk 3 · n 98 · Phase 3 · secondary NCT01149655
  • 0 vs 0.0 wk 2 · n 98 · Phase 3 · secondary NCT01149655
  • 0.0 vs 0.0 wk 1 · n 98 · Phase 3 · secondary NCT01149655
  • -0.8 vs -0.5 wk 28 · n 136 · Phase 3 · secondary NCT01795547
  • -1.3 vs -1.6 wk 6 · n 33 · Phase 3 · secondary NCT02054702
  • -0.1 vs -0.3 wk 104 · n 44 · Phase 3 · secondary NCT00216476
Aripiprazole (Abilify Maintena)
-1.4 vs -0.6−0.8 vs placebo400/300 mg · wk 10 · n 162NCT01663532
6 other results
  • -1.3 vs -0.6 400/300 mg · wk 8 · n 162 · Phase 3 · secondary NCT01663532
  • -1.2 vs -0.5 400/300 mg · wk 6 · n 162 · Phase 3 · secondary NCT01663532
  • -1 vs -0.4 400/300 mg · wk 4 · n 162 · Phase 3 · secondary NCT01663532
  • -0.8 vs -0.4 400/300 mg · wk 2 · n 162 · Phase 3 · secondary NCT01663532
  • -0.4 vs -0.2 400/300 mg · wk 1 · n 162 · Phase 3 · secondary NCT01663532
  • -0.8 vs -0.5 wk 28 · n 136 · Phase 3 · secondary NCT01795547

PANSS response

Aripiprazole (Abilify)
—Not posted · NCT03485417
Aripiprazole (Abilify Maintena)
37% vs 14.3%+22.7 vs placebo400/300 mg · wk 10 · n 162NCT01663532

PSP, change

Aripiprazole (Abilify)
—Not posted · NCT03485417
Aripiprazole (Abilify Maintena)
12.3 vs 5.2+7.1 vs placebo400/300 mg · wk 10 · n 139NCT01663532

Relapse (% of patients)

Aripiprazole (Abilify)
19.4% vs 37.5%−18.1 vs placebowk 52 · n 98NCT01149655
1 other result
  • 10% vs 39.6% wk 52 · n 269 · Phase 3 · secondary NCT00705783
Aripiprazole (Abilify Maintena)
10% vs 39.6%−29.6 vs placebowk 52 · n 269NCT00705783
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
35 other shared endpoints and safety

Coverage. Aripiprazole (Abilify): 39 of 39 rows · Aripiprazole (Abilify Maintena): 39 of 39 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricAripiprazole (Abilify)
Rows use multiple source trials
Aripiprazole (Abilify Maintena)
Rows use multiple source trials
All-cause Discontinuation
responder rate · % of participants
No placebo or comparator arm
20.6% (n=1081) @ 52wk400/300 mg IM Depota,b
NCT00731549 · Phase 3 · registry result, not featured evidence
20.6% (n=1081) @ 52wk400/300 mg IM Depota,b
NCT00731549 · Phase 3 · registry result, not featured evidence
CGI-I
absolute value · score
3.38 vs 3.9 placebo score @ 10wka,b
NCT01149655 · Phase 3 · registry result, not featured evidence
2.7 vs 3.7 placebo score @ 10wk400/300 mga,b
NCT01663532 · Phase 3
CGI-I
absolute value · score
Maintenance
3.7 vs 4.53 placebo score @ 52wka,b
NCT00705783 · Phase 3 · registry result, not featured evidence
3.7 vs 4.53 placebo score @ 52wka,b
NCT00705783 · Phase 3 · monotherapy
CGI-I
absolute value · score
No placebo or comparator arm
3.25 score @ 52wk400/300 mg IM Depota,b
NCT00731549 · Phase 3 · registry result, not featured evidence
3.25 score @ 52wk400/300 mg IM Depota,b
NCT00731549 · Phase 3 · registry result, not featured evidence
CGI-I
absolute value · score
No placebo or comparator arm
Last visit (N=1079)
3.35 score @ 52wk400/300 mg IM Depota,b
Last visit (N=1079)
NCT00731549 · Phase 3 · registry result, not featured evidence
3.35 score @ 52wk400/300 mg IM Depota,b
Last visit (N=1079)
NCT00731549 · Phase 3 · registry result, not featured evidence
CGI-S
absolute change · score
Maintenance
0.14 vs 0.66 placebo score @ 52wka,b
NCT00705783 · Phase 3 · registry result, not featured evidence
0.14 vs 0.66 placebo score @ 52wka,b
NCT00705783 · Phase 3 · monotherapy
CGI-S
absolute change · score
No placebo or comparator arm
-0.3 score @ 52wka,b
NCT01942148 · Phase 3 · registry result, not featured evidence
3 other source trials
-0.24 score @ 52wk400/300 mg IM Depot
NCT00731549 · Phase 3 · registry result, not featured evidence
2.3 score @ 52wk10 - 30 mg QD
NCT00239356 · Phase 3 · registry result, not featured evidence
1.1 score @ 52wk5 - 30 mg QD
NCT00239356 · Phase 3 · registry result, not featured evidence
-0.24 score @ 52wk400/300 mg IM Depota,b
NCT00731549 · Phase 3 · registry result, not featured evidence
CGI-S
absolute change · score
No placebo or comparator arm
Last visit (N=1079)
-0.14 score @ 52wk400/300 mg IM Depota,b
Last visit (N=1079)
NCT00731549 · Phase 3 · registry result, not featured evidence
-0.14 score @ 52wk400/300 mg IM Depota,b
Last visit (N=1079)
NCT00731549 · Phase 3 · registry result, not featured evidence
Clinical Remission
responder rate · % of participants
Maintenance
52.9% (n=87) vs 38.7% (n=31) placebo @ 52wka,b
NCT00705783 · Phase 3 · registry result, not featured evidence
52.9% (n=87) vs 38.7% (n=31) placebo @ 52wka,b
NCT00705783 · Phase 3 · monotherapy
Clinical Remission
responder rate · % of participants
No placebo or comparator arm
48.8% (n=215) @ 38wk300 or 400 mgc,a,b
NCT00706654 · Phase 3 · registry result, not featured evidence
show 1 more dose
59.7% (n=72) @ 38wk25 or 50 mg
NCT00706654 · Phase 3 · registry result, not featured evidence
48.8% (n=215) @ 38wk300 or 400 mgc,a,b
NCT00706654 · Phase 3
show 1 more dose
59.7% (n=72) @ 38wk25 or 50 mg
NCT00706654 · Phase 3
Exacerbation
absolute value · percentage points
No placebo or comparator arm
7.12% (n=265) @ 26wk300 or 400 mgc,a,b
NCT00706654 · Phase 3 · registry result, not featured evidence
show 1 more dose
21.8% (n=131) @ 26wk25 or 50 mg
NCT00706654 · Phase 3 · registry result, not featured evidence
7.12% (n=265) @ 26wk300 or 400 mgc,a,b
NCT00706654 · Phase 3
show 1 more dose
21.8% (n=131) @ 26wk25 or 50 mg
NCT00706654 · Phase 3
PANSS
responder rate · % of participants
Maintenance
87.6% (n=267) vs 56% (n=134) placebo @ 52wka,b
NCT00705783 · Phase 3 · registry result, not featured evidence
87.6% (n=267) vs 56% (n=134) placebo @ 52wka,b
NCT00705783 · Phase 3 · monotherapy
PANSS Negative
absolute change · score
No placebo or comparator arm
-0.96 score @ 4wk400mgc,a,b
NCT01552772 · Phase 1 · registry result, not featured evidence
show 1 more dose
-0.92 score @ 4wk400mg
NCT01552772 · Phase 1 · registry result, not featured evidence
-0.96 score @ 4wk400mgc,a,b
NCT01552772 · Phase 1 · registry result, not featured evidence
show 1 more dose
-0.92 score @ 4wk400mg
NCT01552772 · Phase 1 · registry result, not featured evidence
PANSS Negative Subscale
absolute change · score
-0.33 vs 0.71 placebo score @ 10wka,b
NCT01149655 · Phase 3 · registry result, not featured evidence
-4.5 vs -1.6 placebo score @ 10wk400/300 mga,b
NCT01663532 · Phase 3
PANSS Negative Subscale
absolute change · score
Maintenance
0.19 vs 1.55 placebo score @ 52wka,b
NCT00705783 · Phase 3 · registry result, not featured evidence
0.19 vs 1.55 placebo score @ 52wka,b
NCT00705783 · Phase 3 · monotherapy
PANSS Negative Subscale
absolute change · score
No placebo or comparator arm
-1.6 score @ 24wkd,a,b,e
NCT01432444 · Phase 3 · registry result, not featured evidence
-0.33 score @ 20wk400 mgd,a,b,e
NCT01909466 · Phase 1 · registry result, not featured evidence
PANSS Positive
absolute change · score
No placebo or comparator arm
-1.28 score @ 4wk400mgc,a,b
NCT01552772 · Phase 1 · registry result, not featured evidence
show 1 more dose
-1.25 score @ 4wk400mg
NCT01552772 · Phase 1 · registry result, not featured evidence
-1.28 score @ 4wk400mgc,a,b
NCT01552772 · Phase 1 · registry result, not featured evidence
show 1 more dose
-1.25 score @ 4wk400mg
NCT01552772 · Phase 1 · registry result, not featured evidence
PANSS Positive Subscale
absolute change · score
-0.16 vs 1.63 placebo score @ 10wka,b
NCT01149655 · Phase 3 · registry result, not featured evidence
-10 vs -4.9 placebo score @ 10wk400/300 mga,b
NCT01663532 · Phase 3
PANSS Positive Subscale
absolute change · score
Maintenance
0.44 vs 4.25 placebo score @ 52wka,b
NCT00705783 · Phase 3 · registry result, not featured evidence
0.44 vs 4.25 placebo score @ 52wka,b
NCT00705783 · Phase 3 · monotherapy
PANSS Positive Subscale
absolute change · score
No placebo or comparator arm
-3 score @ 24wkd,a,b,e
NCT01432444 · Phase 3 · registry result, not featured evidence
-0.52 score @ 20wk400 mgd,a,b,e
NCT01909466 · Phase 1 · registry result, not featured evidence
PANSS Total
absolute change · score
Maintenance
1.43 vs 11.55 placebo score @ 52wka,b
NCT00705783 · Phase 3 · registry result, not featured evidence
1.43 vs 11.55 placebo score @ 52wka,b
NCT00705783 · Phase 3 · monotherapy
PANSS Total
absolute change · score
No placebo or comparator arm
-7.9 score @ 52wka,b
NCT01942148 · Phase 3 · registry result, not featured evidence
1 other source trial
-3.55 score @ 52wk400/300 mg IM Depot
NCT00731549 · Phase 3 · registry result, not featured evidence
-3.55 score @ 52wk400/300 mg IM Depota,b
NCT00731549 · Phase 3 · registry result, not featured evidence
PANSS Total
absolute change · score
No placebo or comparator arm
Last visit (N=1078)
-1.72 score @ 52wk400/300 mg IM Depota,b
Last visit (N=1078)
NCT00731549 · Phase 3 · registry result, not featured evidence
-1.72 score @ 52wk400/300 mg IM Depota,b
Last visit (N=1078)
NCT00731549 · Phase 3 · registry result, not featured evidence
QLS Total
absolute change · score
7.47 vs 2.8 Paliperidone score @ 28wka,b
NCT01795547 · Phase 3 · registry result, not featured evidence
7.47 vs 2.8 Paliperidone score @ 28wka,b
NCT01795547 · Phase 3 · registry result, not featured evidence
QLS Total
absolute change · score
No placebo or comparator arm
2.32 score @ 24wka,b
NCT01959035 · Phase 3 · registry result, not featured evidence
2.32 score @ 24wka,b
NCT01959035 · Phase 3 · registry result, not featured evidence
Relapse
event count · % of participants
No placebo or comparator arm
0.3% (n=1081) @ 52wk400/300 mg IM Depotc,a,b
NCT00731549 · Phase 3 · registry result, not featured evidence
show 1 more dose
8.2% (n=1079) @ 52wk400/300 mg IM Depot
NCT00731549 · Phase 3 · registry result, not featured evidence
0.3% (n=1081) @ 52wk400/300 mg IM Depotc,a,b
NCT00731549 · Phase 3 · registry result, not featured evidence
show 1 more dose
8.2% (n=1079) @ 52wk400/300 mg IM Depot
NCT00731549 · Phase 3 · registry result, not featured evidence
Relapse Free
responder rate · % of participants
No placebo or comparator arm
98.96% (n=1081) @ 52wk400/300 mg IM Depota,b
NCT00731549 · Phase 3 · registry result, not featured evidence
98.96% (n=1081) @ 52wk400/300 mg IM Depota,b
NCT00731549 · Phase 3 · registry result, not featured evidence
Relapse Free
responder rate · % of participants
No placebo or comparator arm
Last visit (N=1072)
94.96% (n=1081) @ 52wk400/300 mg IM Depota,b
Last visit (N=1072)
NCT00731549 · Phase 3 · registry result, not featured evidence
94.96% (n=1081) @ 52wk400/300 mg IM Depota,b
Last visit (N=1072)
NCT00731549 · Phase 3 · registry result, not featured evidence
Relapse Occurrence
responder rate · % of participants
No placebo or comparator arm
Overall (N=1079)
8.25% (n=1081) @ 52wk400/300 mg IM Depota,b
Overall (N=1079)
NCT00731549 · Phase 3 · registry result, not featured evidence
8.25% (n=1081) @ 52wk400/300 mg IM Depota,b
Overall (N=1079)
NCT00731549 · Phase 3 · registry result, not featured evidence
Remission
responder rate · % of participants
No placebo or comparator arm
51.7% (n=1081) @ 52wk400/300 mg IM Depota,b
NCT00731549 · Phase 3 · registry result, not featured evidence
51.7% (n=1081) @ 52wk400/300 mg IM Depota,b
NCT00731549 · Phase 3 · registry result, not featured evidence
Responder
responder rate · % of participants
No placebo or comparator arm
89.8% (n=264) @ 38wk300 or 400 mgc,a,b
NCT00706654 · Phase 3 · registry result, not featured evidence
show 1 more dose
75.2% (n=129) @ 38wk25 or 50 mg
NCT00706654 · Phase 3 · registry result, not featured evidence
89.8% (n=264) @ 38wk300 or 400 mgc,a,b
NCT00706654 · Phase 3
show 1 more dose
75.2% (n=129) @ 38wk25 or 50 mg
NCT00706654 · Phase 3
SWN-K Total
absolute change · score
4.82 vs 3.81 Paliperidone score @ 28wka,b
NCT01795547 · Phase 3 · registry result, not featured evidence
4.82 vs 3.81 Paliperidone score @ 28wka,b
NCT01795547 · Phase 3 · registry result, not featured evidence
SWN-K Total
absolute change · score
No placebo or comparator arm
0.19 score @ 24wka,b
NCT01959035 · Phase 3 · registry result, not featured evidence
0.19 score @ 24wka,b
NCT01959035 · Phase 3 · registry result, not featured evidence
Time to Exacerbation
time to event · months
Maintenance
NA vs 6.87 placebo months @ 52wka,b
NCT00705783 · Phase 3 · registry result, not featured evidence
NA vs 6.87 placebo months @ 52wka,b
NCT00705783 · Phase 3 · monotherapy
Time to Exacerbation
time to event · months
No placebo or comparator arm
NA months300 or 400 mgc,a,b,f
NCT00706654 · Phase 3 · registry result, not featured evidence
show 1 more dose
NA months25 or 50 mg
NCT00706654 · Phase 3 · registry result, not featured evidence
NA months300 or 400 mgc,a,b,f
NCT00706654 · Phase 3
show 1 more dose
NA months25 or 50 mg
NCT00706654 · Phase 3
Dropout rate
20%g
NCT00345033 · Phase 4 · registry result, not featured evidence
show 30 more results
39.7%
NCT01942148 · Phase 3 · registry result, not featured evidence
12.5%
NCT01959035 · Phase 3 · registry result, not featured evidence
32.4%
NCT01795547 · Phase 3 · registry result, not featured evidence
36.4%
NCT02054702 · Phase 3 · registry result, not featured evidence
—
NCT01149655 · Phase 3 · registry result, not featured evidence
—
NCT01432444 · Phase 3 · registry result, not featured evidence
20.6%400/300 mg IM Depot
NCT00731549 · Phase 3 · registry result, not featured evidence
40.2%10 - 30 mg QD
NCT00239356 · Phase 3 · registry result, not featured evidence
45%5 - 30 mg QD
NCT00239356 · Phase 3 · registry result, not featured evidence
—5 - 30 mg QD
NCT00239356 · Phase 3 · registry result, not featured evidence
—10 - 30 mg QD
NCT00239356 · Phase 3 · registry result, not featured evidence
—300 or 400 mg
NCT00706654 · Phase 3 · registry result, not featured evidence
—25 or 50 mg
NCT00706654 · Phase 3 · registry result, not featured evidence
84.7%
NCT01001702 · Phase 3 · registry result, not featured evidence
—Aripiprazole Depot
NCT00705783 · Phase 3 · registry result, not featured evidence
—Aripiprazole Depot - Depot Mainten
NCT00705783 · Phase 3 · registry result, not featured evidence
37.8%
NCT00216476 · Phase 3 · registry result, not featured evidence
26.8%
NCT00102518 · Phase 3 · registry result, not featured evidence
16%10 mg/day
NCT00102063 · Phase 3 · registry result, not featured evidence
17.6%30 mg/day
NCT00102063 · Phase 3 · registry result, not featured evidence
14.6%24-30 mg/day
NCT01942161 · Phase 2/3 · registry result, not featured evidence
20%6-12 mg/day
NCT01942161 · Phase 2/3 · registry result, not featured evidence
22.9%2 mg/day
NCT01942161 · Phase 2/3 · registry result, not featured evidence
11.1%400 mg
NCT01646827 · Phase 1 · registry result, not featured evidence
26.3%400 mg
NCT01646827 · Phase 1 · registry result, not featured evidence
6.7%400mg
NCT01552772 · Phase 1 · registry result, not featured evidence
0%30 mg
NCT00102479 · Phase 1 · registry result, not featured evidence
0%25 mg
NCT00102479 · Phase 1 · registry result, not featured evidence
0%20 mg
NCT00102479 · Phase 1 · registry result, not featured evidence
16.7%
NCT01338298 · Phase na · registry result, not featured evidence
—300 or 400 mgg
NCT00706654 · Phase 3
show 13 more results
—25 or 50 mg
NCT00706654 · Phase 3
—Aripiprazole Depot
NCT00705783 · Phase 3 · monotherapy
—Aripiprazole Depot - Depot Mainten
NCT00705783 · Phase 3 · monotherapy
44%400/300 mg
NCT01663532 · Phase 3
26.1%
NCT02360319 · Phase 4 · registry result, not featured evidence
12.5%
NCT01959035 · Phase 3 · registry result, not featured evidence
32.4%
NCT01795547 · Phase 3 · registry result, not featured evidence
39.2%400/300 mg
NCT01683058 · Phase 3 · registry result, not featured evidence
20.6%400/300 mg IM Depot
NCT00731549 · Phase 3 · registry result, not featured evidence
—400 mg
NCT01909466 · Phase 1 · registry result, not featured evidence
11.1%400 mg
NCT01646827 · Phase 1 · registry result, not featured evidence
26.3%400 mg
NCT01646827 · Phase 1 · registry result, not featured evidence
6.7%400mg
NCT01552772 · Phase 1 · registry result, not featured evidence
Discontinued due to AEs
—g
NCT00345033 · Phase 4 · registry result, not featured evidence
show 30 more results
5.9%
NCT01942148 · Phase 3 · registry result, not featured evidence
5.7%
NCT01959035 · Phase 3 · registry result, not featured evidence
10.8%
NCT01795547 · Phase 3 · registry result, not featured evidence
3%
NCT02054702 · Phase 3 · registry result, not featured evidence
—
NCT01149655 · Phase 3 · registry result, not featured evidence
—
NCT01432444 · Phase 3 · registry result, not featured evidence
2.9%400/300 mg IM Depot
NCT00731549 · Phase 3 · registry result, not featured evidence
6.2%10 - 30 mg QD
NCT00239356 · Phase 3 · registry result, not featured evidence
0%5 - 30 mg QD
NCT00239356 · Phase 3 · registry result, not featured evidence
—5 - 30 mg QD
NCT00239356 · Phase 3 · registry result, not featured evidence
—10 - 30 mg QD
NCT00239356 · Phase 3 · registry result, not featured evidence
—300 or 400 mg
NCT00706654 · Phase 3 · registry result, not featured evidence
—25 or 50 mg
NCT00706654 · Phase 3 · registry result, not featured evidence
8.2%
NCT01001702 · Phase 3 · registry result, not featured evidence
—Aripiprazole Depot
NCT00705783 · Phase 3 · registry result, not featured evidence
—Aripiprazole Depot - Depot Mainten
NCT00705783 · Phase 3 · registry result, not featured evidence
2.2%
NCT00216476 · Phase 3 · registry result, not featured evidence
—
NCT00102518 · Phase 3 · registry result, not featured evidence
7%10 mg/day
NCT00102063 · Phase 3 · registry result, not featured evidence
3.9%30 mg/day
NCT00102063 · Phase 3 · registry result, not featured evidence
12.2%24-30 mg/day
NCT01942161 · Phase 2/3 · registry result, not featured evidence
6.7%6-12 mg/day
NCT01942161 · Phase 2/3 · registry result, not featured evidence
2.9%2 mg/day
NCT01942161 · Phase 2/3 · registry result, not featured evidence
—400 mg
NCT01646827 · Phase 1 · registry result, not featured evidence
—400 mg
NCT01646827 · Phase 1 · registry result, not featured evidence
1.7%400mg
NCT01552772 · Phase 1 · registry result, not featured evidence
—30 mg
NCT00102479 · Phase 1 · registry result, not featured evidence
—25 mg
NCT00102479 · Phase 1 · registry result, not featured evidence
—20 mg
NCT00102479 · Phase 1 · registry result, not featured evidence
—
NCT01338298 · Phase na · registry result, not featured evidence
—300 or 400 mgg
NCT00706654 · Phase 3
show 13 more results
—25 or 50 mg
NCT00706654 · Phase 3
—Aripiprazole Depot
NCT00705783 · Phase 3 · monotherapy
—Aripiprazole Depot - Depot Mainten
NCT00705783 · Phase 3 · monotherapy
4.2%400/300 mg
NCT01663532 · Phase 3
—
NCT02360319 · Phase 4 · registry result, not featured evidence
5.7%
NCT01959035 · Phase 3 · registry result, not featured evidence
10.8%
NCT01795547 · Phase 3 · registry result, not featured evidence
8.1%400/300 mg
NCT01683058 · Phase 3 · registry result, not featured evidence
2.9%400/300 mg IM Depot
NCT00731549 · Phase 3 · registry result, not featured evidence
—400 mg
NCT01909466 · Phase 1 · registry result, not featured evidence
—400 mg
NCT01646827 · Phase 1 · registry result, not featured evidence
—400 mg
NCT01646827 · Phase 1 · registry result, not featured evidence
1.7%400mg
NCT01552772 · Phase 1 · registry result, not featured evidence
Serious AEs
0%g
NCT00345033 · Phase 4 · registry result, not featured evidence
show 30 more results
10.3%
NCT01942148 · Phase 3 · registry result, not featured evidence
3.4%
NCT01959035 · Phase 3 · registry result, not featured evidence
8.3%
NCT01795547 · Phase 3 · registry result, not featured evidence
3%
NCT02054702 · Phase 3 · registry result, not featured evidence
3.1%
NCT01149655 · Phase 3 · registry result, not featured evidence
14.2%
NCT01432444 · Phase 3 · registry result, not featured evidence
8.8%400/300 mg IM Depot
NCT00731549 · Phase 3 · registry result, not featured evidence
—10 - 30 mg QD
NCT00239356 · Phase 3 · registry result, not featured evidence
—5 - 30 mg QD
NCT00239356 · Phase 3 · registry result, not featured evidence
0%5 - 30 mg QD
NCT00239356 · Phase 3 · registry result, not featured evidence
13.4%10 - 30 mg QD
NCT00239356 · Phase 3 · registry result, not featured evidence
5.7%300 or 400 mg
NCT00706654 · Phase 3 · registry result, not featured evidence
8.4%25 or 50 mg
NCT00706654 · Phase 3 · registry result, not featured evidence
12.9%
NCT01001702 · Phase 3 · registry result, not featured evidence
—Aripiprazole Depot
NCT00705783 · Phase 3 · registry result, not featured evidence
4.1%Aripiprazole Depot - Depot Mainten
NCT00705783 · Phase 3 · registry result, not featured evidence
15.6%
NCT00216476 · Phase 3 · registry result, not featured evidence
6.2%
NCT00102518 · Phase 3 · registry result, not featured evidence
4%10 mg/day
NCT00102063 · Phase 3 · registry result, not featured evidence
3.9%30 mg/day
NCT00102063 · Phase 3 · registry result, not featured evidence
4.9%24-30 mg/day
NCT01942161 · Phase 2/3 · registry result, not featured evidence
6.7%6-12 mg/day
NCT01942161 · Phase 2/3 · registry result, not featured evidence
0%2 mg/day
NCT01942161 · Phase 2/3 · registry result, not featured evidence
0%400 mg
NCT01646827 · Phase 1 · registry result, not featured evidence
0%400 mg
NCT01646827 · Phase 1 · registry result, not featured evidence
1.7%400mg
NCT01552772 · Phase 1 · registry result, not featured evidence
0%30 mg
NCT00102479 · Phase 1 · registry result, not featured evidence
0%25 mg
NCT00102479 · Phase 1 · registry result, not featured evidence
0%20 mg
NCT00102479 · Phase 1 · registry result, not featured evidence
0%
NCT01338298 · Phase na · registry result, not featured evidence
5.7%300 or 400 mgg
NCT00706654 · Phase 3
show 13 more results
8.4%25 or 50 mg
NCT00706654 · Phase 3
—Aripiprazole Depot
NCT00705783 · Phase 3 · monotherapy
4.1%Aripiprazole Depot - Depot Mainten
NCT00705783 · Phase 3 · monotherapy
4.8%400/300 mg
NCT01663532 · Phase 3
29.1%
NCT02360319 · Phase 4 · registry result, not featured evidence
3.4%
NCT01959035 · Phase 3 · registry result, not featured evidence
8.3%
NCT01795547 · Phase 3 · registry result, not featured evidence
6.8%400/300 mg
NCT01683058 · Phase 3 · registry result, not featured evidence
8.8%400/300 mg IM Depot
NCT00731549 · Phase 3 · registry result, not featured evidence
2.9%400 mg
NCT01909466 · Phase 1 · registry result, not featured evidence
0%400 mg
NCT01646827 · Phase 1 · registry result, not featured evidence
0%400 mg
NCT01646827 · Phase 1 · registry result, not featured evidence
1.7%400mg
NCT01552772 · Phase 1 · registry result, not featured evidence
Most frequent reported AEs
g
eye irritation/swelling 6.3% (placebo 0%)
psychiatric decompensation 6.3% (placebo 0%)
psychiatric decompensation 6.3% (placebo 0%)
NCT00345033 · Phase 4 · registry result, not featured evidence
show 27 more results
nasopharyngitis 45.6%
somnolence 20.6%
nausea 17.6%
NCT01942148 · Phase 3 · registry result, not featured evidence
weight increased 6.8%
NCT01959035 · Phase 3 · registry result, not featured evidence
accidental overdose 20.8%
insomnia 11.8%
weight increased 9%
NCT01795547 · Phase 3 · registry result, not featured evidence
akathisia 21.2%
headache 12.1%
constipation 9.1%
NCT02054702 · Phase 3 · registry result, not featured evidence
schizophrenia 9.2% (placebo 16.7%)
weight increased 8.2% (placebo 10.4%)
nasopharyngitis 7.1% (placebo 2.1%)
NCT01149655 · Phase 3 · registry result, not featured evidence
insomnia 6.7%
akathisia 6.3%
weight increased 2.3%
NCT01432444 · Phase 3 · registry result, not featured evidence
400/300 mg IM Depot
headache 7.6%
nasopharyngitis 7%
anxiety 6.8%
NCT00731549 · Phase 3 · registry result, not featured evidence
5 - 30 mg QD
pyrexia 35%
headache 30%
cough 15%
NCT00239356 · Phase 3 · registry result, not featured evidence
10 - 30 mg QD
back pain 7.2%
anxiety 6.2%
headache 6.2%
NCT00239356 · Phase 3 · registry result, not featured evidence
300 or 400 mg
insomnia 11.7%
akathisia 10.6%
headache 9.8%
NCT00706654 · Phase 3 · registry result, not featured evidence
25 or 50 mg
insomnia 13.7%
back pain 11.5%
weight decreased 9.2%
NCT00706654 · Phase 3 · registry result, not featured evidence
headache 15.3%
influenza 10.6%
weight increased 10.6%
NCT01001702 · Phase 3 · registry result, not featured evidence
insomnia 10% (placebo 9%)
weight increased 9.7% (placebo 9.7%)
anxiety 5.9% (placebo 7.5%)
NCT00705783 · Phase 3 · registry result, not featured evidence
insomnia 24.4%
anxiety 15.6%
headache 11.1%
NCT00216476 · Phase 3 · registry result, not featured evidence
extrapyramidal disorder 14.8%
somnolence 12.9%
headache 9.5%
NCT00102518 · Phase 3 · registry result, not featured evidence
10 mg/day
headache 16% (placebo 10%)
extrapyramidal disorder 13% (placebo 5%)
insomnia 11% (placebo 15%)
NCT00102063 · Phase 3 · registry result, not featured evidence
30 mg/day
extrapyramidal disorder 21.6% (placebo 5%)
somnolence 21.6% (placebo 6%)
tremor 11.8% (placebo 2%)
NCT00102063 · Phase 3 · registry result, not featured evidence
24-30 mg/day
nausea 22%
insomnia 17.1%
salivary hypersecretion 14.6%
NCT01942161 · Phase 2/3 · registry result, not featured evidence
6-12 mg/day
insomnia 20%
somnolence 20%
epistaxis 13.3%
NCT01942161 · Phase 2/3 · registry result, not featured evidence
2 mg/day
nausea 20%
insomnia 14.3%
nasopharyngitis 14.3%
NCT01942161 · Phase 2/3 · registry result, not featured evidence
400 mg
injection site pain 35.3%
headache 23.5%
akathisia 17.6%
NCT01646827 · Phase 1 · registry result, not featured evidence
400 mg
injection site pain 27.8%
headache 22.2%
akathisia 16.7%
NCT01646827 · Phase 1 · registry result, not featured evidence
400mg
injection site pain 6.7%
toothache 6.7%
blood creatine phosphokinase increased 5%
NCT01552772 · Phase 1 · registry result, not featured evidence
30 mg
headache 50%
sedation 33.3%
abdominal pain upper 16.7%
NCT00102479 · Phase 1 · registry result, not featured evidence
25 mg
abdominal pain upper 42.9%
acne 28.6%
dizziness 28.6%
NCT00102479 · Phase 1 · registry result, not featured evidence
20 mg
headache 50%
insomnia 25%
musculoskeletal stiffness 25%
NCT00102479 · Phase 1 · registry result, not featured evidence
nausea 50% (placebo 22.2%)
vomiting 50% (placebo 38.9%)
diarrhea 45% (placebo 38.9%)
NCT01338298 · Phase na · registry result, not featured evidence
300 or 400 mgg
insomnia 11.7%
akathisia 10.6%
headache 9.8%
NCT00706654 · Phase 3
show 12 more results
25 or 50 mg
insomnia 13.7%
back pain 11.5%
weight decreased 9.2%
NCT00706654 · Phase 3
insomnia 10% (placebo 9%)
weight increased 9.7% (placebo 9.7%)
anxiety 5.9% (placebo 7.5%)
NCT00705783 · Phase 3 · monotherapy
400/300 mg
weight increased 16.8% (placebo 7%)
headache 14.4% (placebo 16.3%)
akathisia 11.4% (placebo 3.5%)
NCT01663532 · Phase 3
weight gain 14.4%
anxiety 12.2%
depression 10.4%
NCT02360319 · Phase 4 · registry result, not featured evidence
weight increased 6.8%
NCT01959035 · Phase 3 · registry result, not featured evidence
accidental overdose 20.8%
insomnia 11.8%
weight increased 9%
NCT01795547 · Phase 3 · registry result, not featured evidence
400/300 mg
weight increased 29.7%
akathisia 12.2%
headache 8.1%
NCT01683058 · Phase 3 · registry result, not featured evidence
400/300 mg IM Depot
headache 7.6%
nasopharyngitis 7%
anxiety 6.8%
NCT00731549 · Phase 3 · registry result, not featured evidence
400 mg
injection site pain 27.5%
weight increased 12.3%
headache 11.6%
NCT01909466 · Phase 1 · registry result, not featured evidence
400 mg
injection site pain 35.3%
headache 23.5%
akathisia 17.6%
NCT01646827 · Phase 1 · registry result, not featured evidence
400 mg
injection site pain 27.8%
headache 22.2%
akathisia 16.7%
NCT01646827 · Phase 1 · registry result, not featured evidence
400mg
injection site pain 6.7%
toothache 6.7%
blood creatine phosphokinase increased 5%
NCT01552772 · Phase 1 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for both studies.
  2. bTreatment context has not been resolved for both arms.
  3. cThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  4. dTrial phases differ: Phase 3 versus Phase 1.
  5. eAssessment timepoints differ: 24 weeks versus 20 weeks.
  6. fThe assessment timepoint is not available for both results.
  7. gPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Aripiprazole (Abilify)

Total Cholesterol Change mg/dL -15.3 vs 5.6 placebo mg/dL @ 8wk
absolute change · mg/dL
NCT00345033 · Phase 4 · registry result, not featured evidence
Weight -1.5 vs 0.3 placebo kg @ 8wk
absolute change · kg
NCT00345033 · Phase 4 · registry result, not featured evidence
BMI -0.52 vs 0.03 placebo kg @ 8wk
absolute change · kg
NCT00345033 · Phase 4 · registry result, not featured evidence
Insulin Sensitivity 0.003 vs -0.005 placebo minutes @ 8wk
absolute change · minutes
NCT00345033 · Phase 4 · registry result, not featured evidence
Triglyceride Change mg/dL -5.9 vs -7.3 placebo mg/dL @ 8wk
absolute change · mg/dL
NCT00345033 · Phase 4 · registry result, not featured evidence
HOMA-IR 0.6 vs 0.65 placebo score @ 8wk
absolute change · score
NCT00345033 · Phase 4 · registry result, not featured evidence
CGAS 8.6 score @ 6.14wk24-30 mg/day
absolute change · score
No placebo or comparator arm
NCT01942161 · Phase 2/3 · registry result, not featured evidence
show 3 more results
8.5 score @ 6.14wk6-12 mg/day
NCT01942161 · Phase 2/3 · registry result, not featured evidence
10.5 score @ 6.14wk2 mg/day
NCT01942161 · Phase 2/3 · registry result, not featured evidence
5.6 score @ 52wk
NCT01942148 · Phase 3 · registry result, not featured evidence
Cognitive Composite Z Score -0.024 vs 0.045 Brexpiprazole Z-score @ 6wk
absolute change · Z-score
NCT02054702 · Phase 3 · registry result, not featured evidence
show 1 more result
0.113 vs -0.01 Brexpiprazole Z-score @ 6wk
NCT02054702 · Phase 3 · registry result, not featured evidence
CGI-I 2.7 vs 2.5 Brexpiprazole score @ 6wk
absolute change · score
NCT02054702 · Phase 3 · registry result, not featured evidence
Overall 48.5% (n=33) vs 60.9% (n=64) Brexpiprazole @ 6wk
responder rate · % of participants
NCT02054702 · Phase 3 · registry result, not featured evidence
SLOF Total 6 vs 7.5 Brexpiprazole score @ 6wk
absolute change · score
NCT02054702 · Phase 3 · registry result, not featured evidence
Relapse 19.39% (n=98) vs 37.5% (n=48) placebo @ 52wk
event count · % of participants
NCT01149655 · Phase 3 · registry result, not featured evidence

+ 16 further endpoints in the CSV export.

Aripiprazole (Abilify Maintena)

PSP 12.3 vs 5.2 placebo score @ 10wk400/300 mg
absolute change · score
NCT01663532 · Phase 3
PANSS 37% (n=162) vs 14.3% (n=168) placebo @ 10wk400/300 mg
responder rate · % of participants
NCT01663532 · Phase 3 · converted to % from 60 participants as posted
Time to First Hospitalisation 20.16 vs 17.43 Clinician's Choice months
time to event · months
NCT02360319 · Phase 4 · registry result, not featured evidence · converted to months from 613.7 days as posted
BPRS Total 31.31 vs 30.7 Clinician's Choice score @ 52wk
absolute change · score
NCT02360319 · Phase 4 · registry result, not featured evidence
show 1 more result
30.87 vs 30.73 Clinician's Choice score @ 104wk
NCT02360319 · Phase 4 · registry result, not featured evidence
RBANS Total 178.2 vs 189.2 Clinician's Choice score @ 52wk
absolute change · score
NCT02360319 · Phase 4 · registry result, not featured evidence
show 1 more result
180.8 vs 194.1 Clinician's Choice score @ 104wk
NCT02360319 · Phase 4 · registry result, not featured evidence
SWN-K Mental Functioning -0.18 score @ 8wk400 mg
absolute change · score
No placebo or comparator arm
NCT01909466 · Phase 1 · registry result, not featured evidence
show 1 more result
0.01 score @ 20wk400 mg
NCT01909466 · Phase 1 · registry result, not featured evidence
SWN-K Self Control -0.47 score @ 8wk400 mg
absolute change · score
No placebo or comparator arm
NCT01909466 · Phase 1 · registry result, not featured evidence
show 1 more result
-0.64 score @ 20wk400 mg
NCT01909466 · Phase 1 · registry result, not featured evidence
SWN-K Physical Functioning -0.39 score @ 8wk400 mg
absolute change · score
No placebo or comparator arm
NCT01909466 · Phase 1 · registry result, not featured evidence
show 1 more result
-0.37 score @ 20wk400 mg
NCT01909466 · Phase 1 · registry result, not featured evidence
SWN-K Emotional Regulation 0.3 score @ 8wk400 mg
absolute change · score
No placebo or comparator arm
NCT01909466 · Phase 1 · registry result, not featured evidence
show 1 more result
0.46 score @ 20wk400 mg
NCT01909466 · Phase 1 · registry result, not featured evidence
SWN-K Social Integration -0.47 score @ 8wk400 mg
absolute change · score
No placebo or comparator arm
NCT01909466 · Phase 1 · registry result, not featured evidence
show 1 more result
-0.32 score @ 20wk400 mg
NCT01909466 · Phase 1 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Aripiprazole (Abilify)'s landscape · Aripiprazole (Abilify Maintena)'s landscape